A Randomized, Open-label, Multicentre, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab (msb0010718c) In Combination With And/or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100
This is a Phase 3, open-label, international, multi-centre, efficacy, and safety study of
avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients
must have previously untreated, histologically confirmed Stage II-IV epithelial ovarian
(EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for
The primary purpose of the study is to demonstrate if avelumab given as single agent in the
maintenance setting following frontline chemotherapy or in combination with
carboplatin/paclitaxel is superior to platinum-based chemotherapy alone followed by
observation in this population of newly diagnosed ovarian cancer patients.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society